Search
Affitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAffitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.
MD-0727
go.drugbank.com/drugs/DB05948InvestigationalMD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.
DTX-101
go.drugbank.com/drugs/DB17699InvestigationalIt was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103] … DTX-101 is an investigational gene therapy consisting of an adeno-associated virus serotype Rh10 vector encoding the human Factor Ix gene.
Coagulin-B
go.drugbank.com/drugs/DB17703Experimental[A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation
Retezorogant
go.drugbank.com/drugs/DB21592ExperimentalThe usage of the INN stem '-rogant' in the name indicates that Retezorogant is a retinoic acid receptor-related orphan receptor gamma (RORY) antagonist and inverse agonist.
ST-36
go.drugbank.com/drugs/DB17275ExperimentalIn 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]
BN‐Brachyury vaccine
go.drugbank.com/drugs/DB17425ExperimentalIt is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)‐Brachyury booster vaccine.[A255173]
JNJ-26489112
go.drugbank.com/drugs/DB15203InvestigationalJNJ-26489112 is under investigation in clinical trial NCT00579384 (A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive
Resiniferatoxin
go.drugbank.com/drugs/DB06515InvestigationalResiniferatoxin (RTX) is a naturally occurring, ultrapotent capsaicin analog that activates the vanilloid receptor in a subpopulation of primary afferent sensory neurons involved in nociception (the transmission
Psilocybin
go.drugbank.com/drugs/DB11664InvestigationalPsilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.